Determination of Glomerular Filtration Rate After Contrast-Enhanced CT Among Critically Ill Patients: Support for a New Procedure

危重患者增强CT后肾小球滤过率测定:支持一项新程序

阅读:1

Abstract

OBJECTIVES: To measure glomerular filtration rate using iohexol plasma clearance (mGFRiohexol) in critically ill patients using the high doses of iohexol administered at CT and to evaluate its agreements with urinary creatinine clearance (uClcr) and estimated glomerular filtration rates (eGFRs), calculated from plasma concentrations of creatinine (eGFRcr) and cystatin C (eGFRcys). DESIGN: Prospective observational cohort study. SETTING: ICUs across Southeast Sweden. PATIENTS: Critically ill adult patients. INTERVENTIONS AND MEASUREMENTS: Twenty-six ICU patients were given high doses of iohexol (range, 27-140 mL) for contrast-enhanced CT, whereafter blood samples were taken in the elimination phase for determination of mGFRiohexol. Plasma iohexol concentrations were determined by high-performance liquid chromatography and mGFRiohexol was calculated. Standard dose (5 mL) of iohexol was administered the following days to compare low-dose clearance results with the high-dose clearance results. Six-hour uClcr was performed four times a day and averaged. MAIN RESULTS: Mean ± sd mGFRiohexol after CT was 77.4 ± 38.1 mL/min (n = 26), and uClcr was 97.3 ± 58.2 mL/min (n = 25) in the critically ill patients. There was a strong positive correlation between mGFRiohexol determined with high and low doses of iohexol in patients with normal or high mGFRiohexol (coefficient of determination [R2] = 0.88; p < 0.001) and between mGFRiohexol and uClcr (R2 = 0.87; p < 0.001). eGFRcr overestimated mGFRiohexol and eGFRcys underestimated mGFRiohexol. CONCLUSIONS: mGFRiohexol after contrast-enhanced CT compares well with mGFRiohexol after standard low-dose iohexol respectively uClcr. Over- and underestimation of mGFRiohexol by eGFRcr and eGFRcys is probably explained by increased tubular secretion of creatinine and increased production of cystatin C in intensive care patients.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。